BioMimetic boss sells more shares
Posted on October 26, 2009 at 7:56 am
BioMimetic president and CEO Sam Lynch last week sold 9,000 shares of the company (Ticker: BMTI) as part of a trading plan. He still owns almost 900,000 shares that are worth more than $11 million.
permalink | Comment on this post
Brentwood lab gets nod for H1N1 test
Posted on October 14, 2009 at 7:51 amDiatherix Laboratories has been authorized by the Food and Drug Administration to market its H1N1-09 Influenza Test. Diatherix CEO Dennis Grimaud said the testing panel also can identify any co-infections like pneumonia, which have contributed to many H1N1 deaths.
permalink | Comment on this post
A pop for BioMimetic
Posted on October 6, 2009 at 1:25 pm
Shares of BioMimetic (Ticker: BMTI) are up more than 10 percent at 1:20 p.m. on no apparent news. Volume also isn’t raising any flags, with only about 1.8 times the daily average number of shares having traded hands so far.
UPDATE: OptionMonster’s David Russell has some clues: It appears some investors are betting on good news coming out of a presentation later this week.
permalink | Comment on this post
Local E&Y addition to biotech group
Posted on September 29, 2009 at 8:37 amJeff Smith, a partner at Ernst & Young’s Nashville office, has been named to the Tennessee Biotechnology Association’s board of directors. Four folks from the Memphis area also have joined the group.
permalink | Comment on this post
Franklin co. ‘overvalued,’ says AFG
Posted on July 8, 2009 at 10:15 amBioMimetic Therapeutics made a list of “15 Overvalued Small Cap Stocks” as rated by Applied Finance Group.
The 15 firms listed below all meet AFG’s Sell Criteria and all look extremely overvalued according to AFG’s valuation model. These companies all possess the characteristics of a bad investment and may be a potential torpedo lurking in your portfolio. AFG has proven successful since 1996 at identifying good companies as well as sell opportunities, providing a solid buy/sell spread.
permalink | Comment on this post
BioMimetic puts a bow on its offering
Posted on June 23, 2009 at 10:24 pmThe Franklin-based biotech has raised $17 million from a rights offering. The company (Ticker: BMTI) had enlisted Novo A/S, its largest shareholder, as a backstop but ended up with more demand that it had shares to sell.
permalink | Comment on this post
BioMimetic extends rights offering
Posted on June 11, 2009 at 4:41 pmThe Franklin-based biotech, which is trying to raise $17 million to give it a cash buffer, has extended the deadline of its rights offering by a week. Over in Denmark, the folks at Novo – who have pledged to backstop the offering – are pulling out their checkbook…
permalink | Comment on this post
BioMimetic lightens its auction-rate load
Posted on April 15, 2009 at 10:42 pmIn registering papers related to its upcoming $17 million rights offering, the Franklin-based biotech (Ticker: BMTI) says it last week sold $6 million worth of auction-rate securities at full value. The securities had been in limbo since the auction-rate market seized up early last year, stinging many a company, including Nashville-based Louisiana-Pacific.
On a related note, the company has filed an arbitration claim against Deutsche Bank Securities over auction-rate securities it bought on behalf of BioMimetic.
permalink | Comment on this post
Gore signs on to embryonic stem cell alternative
Posted on April 14, 2009 at 7:31 amUSA Today reports:
Former vice president Al Gore is entering the stem cell arena with an announcement today of a $20 million biotech venture in the hot area of “induced pluripotent” stem cells.
Induced cells are attracting interest from researchers and biotech firms as an alternative to embryonic stem cells. Induced cells are made by inserting four genes into ordinary skin cells, and they offer a new path for “regenerative” medical treatments.
“I just think it’s a very important breakthrough that is filled with promise and hope,” says Gore, a partner with the venture-capital firm Kleiner Perkins Caufield and Byers, which is backing the research. “I think this is one of those good news stories that comes along every once in a while.”
permalink | Comment on this post
Former Senator to advise stem cell venture
Posted on February 12, 2009 at 9:16 amJim Sasser has been named to the advisory board of Maryland-based Neuralstem, which is developing brain and spinal cord stem cells to treat various diseases. Sasser, a former U.S. ambassador to China, will focus on that country.
permalink | Comment on this post
Life sciences venture ramps up in Franklin
Posted on February 3, 2009 at 11:32 amVenture Nashville reports on Nodality, a biotech product development company preparing to launch its operations in April.
Parkinson said researchers in the Nashville lab will primarily be “taking the information we develop out of our discovery labs” in the Bay Area and will be “working to convert [what is learned] into laboratory tests that could eventually be used to inform patient care.”
Recent Comments
In our good state a select few run the place, 20 yrs ago and today....
Southernindie…Unfortunat ely you have suffered a dibilitating...
And…Karl (Marx) Dean is spending one billion dollars...
Someone explain the difference between short stay and observation...
Watching the Chairman of Starwood Hotels yesterday on CNBC...
Funny how the Union’s feel about taxes. They complained about their...
Where is it?
An absolutely ugly structure, which I have always thought did not take...
Too bad that ATT changed the look of the building so that it no longer...
Yeah, well, look at the TN Legislature of good ol’ boys and the...
As long as the red rules, we will be far behind other states. The GOP does...
Nissan CEO Carlos Ghosn: I don’t know what...